r.rotation.to⌕ Search stocks, people, sectors
Following this device: dark.
Request a free account

Follow the people · Insider

PT

Paul Peter Tak

Insider · Chief Executive Officer · CADL

Paul Peter Tak files insider transactions with the SEC as a chief executive officer of Candel Therapeutics. We hold 2 disclosed purchases and sales filed since 2 August 2021, 2 of them in the last 90 days.

  • Files forCADL
  • Disclosed buys and sells2 in all, 2 in the last 90 days
  • Last disclosure11 September 2026

Positions held

1 post we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 29 July 2021 — 11 September 2026Chief Executive Officer · Candel Therapeutics 25 Form 4 lines · source: SEC Form 4

Every transaction

25 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing
25 of 25 shown
11 Sep 202611 Sep 2026SEC Form 40 dsold on the open marketCandel Therapeutics59,379 sharesup +0.0%up +0.0%
10 Sep 202611 Sep 2026SEC Form 41 dexercised options overnot a tradeCandel Therapeutics125,000 sharesdown −6.9%up +0.0%
10 Sep 202611 Sep 2026SEC Form 41 dsold on the open marketCandel Therapeutics220,866 sharesdown −6.9%up +0.0%
10 Sep 202611 Sep 2026SEC Form 41 dexercised options overnot a tradeCandel Therapeuticsderivative125,000 sharesdown −6.9%up +0.0%
26 Jan 202628 Jan 2026SEC Form 42 dwas grantednot a tradeCandel Therapeuticsderivative629,000 sharesup +75.5%up +83.7%
26 Jan 202628 Jan 2026SEC Form 42 dwas grantednot a tradeCandel Therapeuticsderivative629,000 sharesup +75.5%up +83.7%
25 Jun 202526 Jun 2025SEC Form 41 dwas grantednot a tradeCandel Therapeutics42,826 sharesup +117.4%up +109.6%
19 Mar 202520 Mar 2025SEC Form 41 dsold on the open marketCandel Therapeutics400 sharesup +18.5%up +27.8%
18 Mar 202520 Mar 2025SEC Form 42 dsold on the open marketCandel Therapeutics25,772 sharesup +19.6%up +27.8%
12 Feb 202514 Feb 2025SEC Form 42 dwas grantednot a tradeCandel Therapeuticsderivative525,000 sharesup +23.3%up +16.5%
15 Jan 202517 Jan 2025SEC Form 42 dsold on the open marketCandel Therapeutics21,704 sharesup +31.8%up +58.2%
8 Jan 202510 Jan 2025SEC Form 42 dsold on the open marketCandel Therapeutics21,172 sharesup +20.8%up +28.9%
29 Nov 20243 Dec 2024SEC Form 44 dsold on the open marketCandel Therapeutics48,847 sharesup +124.1%up +133.8%
21 Nov 202421 Nov 2024SEC Form 40 dexercised options overnot a tradeCandel Therapeuticsderivative12,900 sharesup +155.0%up +155.0%
21 Nov 202421 Nov 2024SEC Form 40 dexercised options overnot a tradeCandel Therapeutics12,900 sharesup +155.0%up +155.0%
17 Jul 202419 Jul 2024SEC Form 42 dsold on the open marketCandel Therapeutics22,528 sharesup +60.5%up +75.5%
11 Jul 202415 Jul 2024SEC Form 44 dsold on the open marketCandel Therapeutics20,293 sharesup +78.4%up +59.3%
28 Nov 202330 Nov 2023SEC Form 42 dhad shares withheld for taxnot a tradeCandel Therapeutics43,443 sharesup +1071.7%up +1073.0%
26 Nov 202328 Nov 2023SEC Form 42 dwas grantednot a tradeCandel Therapeutics180,108 sharesup +976.0%up +1071.7%
28 Apr 20232 May 2023SEC Form 44 dwas grantednot a tradeCandel Therapeuticsderivative180,000 sharesup +717.4%up +571.7%
9 Dec 202212 Dec 2022SEC Form 43 dbought on the open marketCandel Therapeutics12,935 sharesup +404.5%up +356.5%
8 Dec 202212 Dec 2022SEC Form 44 dbought on the open marketCandel Therapeutics3,050 sharesup +455.0%up +356.5%
28 Nov 202230 Nov 2022SEC Form 42 dwas grantednot a tradeCandel Therapeutics195,906 sharesup +516.7%up +502.6%
28 Feb 20221 Mar 2022SEC Form 41 dwas grantednot a tradeCandel Therapeuticsderivative330,000 sharesup +155.9%up +162.3%
29 Jul 20212 Aug 2021SEC Form 44 dbought on the open marketCandel Therapeutics25,000 sharesup +44.5%up +40.6%

Both percentages are the stock’s move, not Paul Peter Tak’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 11 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 25 of the 25 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.